Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | DRD1 | P21728 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710968 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL30634566 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL30634565 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL5711036 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL5711013 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL5711008 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL5711037 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL5711025 | 0.84 | HTR2A (0.47) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL29833637 | 0.84 | HTR2A (0.47) | ALDH1A1MAPK1TP53HTR2ASLC6A2 | |
| SCHEMBL6961973 | 0.83 | HTR2A (0.68) | ALDH1A1MAPK1TP53HTR2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | LCS GROUP, LLC (US) | 2011-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021564-A1 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR | COMT, MC4R, SLC6A4 | ALDH1A1 400/4885MAPK1 4788/4885TP53 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.